Hims & Hers Health (NYSE: HIMS) Stock Analysis: Citigroup Raises Price Target Amidst Mixed Q1 Results

Font: Financial Modeling Prep  • May 12, 2026

• Citigroup maintains a Neutral rating on Hims & Hers Health, Inc. (NYSE: HIMS) but raises its price target to $28.
• The company reported a surprise quarterly loss of $0.18 per share, missing consensus estimates.
• Despite the financial miss, Hims & Hers Health raised its 2026 revenue forecast, signaling confidence in future demand for its personalized healthcare offerings.

Hims & Hers Health, Inc. (NYSE: HIMS) is a leading telehealth company that operates a digital platform. It offers a wide range of health and wellness products and provides access to medical consultations directly to consumers. The company focuses on personalized treatments for various conditions, competing in the growing digital health market.

On May 12, 2026, Citigroup maintains its Neutral grade on Hims & Hers Health, issuing a hold action for the stock. In a related move, the firm raises its price target for the company to $28 from a previous target of $24. The stock price was $29.14 when the rating was published.

The neutral rating reflects the company's mixed financial results. Shares experienced a 15% drop in premarket trading after Hims & Hers Health announced a surprise quarterly loss of $0.18 per share. As highlighted by Zacks, this is significantly below the consensus estimate of a $0.04 loss per share.

For the quarter, the company posted revenues of $608.10 million. While this represents an increase from the $586.00 million in revenue from the year-ago quarter, it still missed the consensus revenue estimate. This underperformance is attributed to recent changes in its weight-loss product offerings.

Despite the quarterly miss, the company shows confidence in its future. As highlighted by Reuters, Hims & Hers Health raised its 2026 revenue forecast, expecting strong demand for its personalized healthcare offerings. This positive outlook likely contributes to Citigroup’s decision to raise its price target, even while maintaining a neutral stance.